Teva Pharmaceuticals @TevaUSA
Biosimilar medicines are potentially less expensive than original biologics, whilst having the same effectiveness. Teva’s Cory Wohlbach explains what #biosimilars are and how he is working with government regulators to share his expertise https://t.co/ifooyDwNMy #MeetOurExpert https://t.co/OaxtufTxzZ — PolitiTweet.org